Madhu Kumar
Stock Analyst at Goldman Sachs
(2.85)
# 1,570
Out of 5,165 analysts
142
Total ratings
55.1%
Success rate
19.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $182.02 | +1.64% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $7.44 | -19.35% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $7.68 | +121.35% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.21 | +81.00% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $250.16 | -38.04% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $60.83 | -12.87% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $10.99 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $57.37 | +27.24% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $18.87 | +647.22% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $24.04 | +41.43% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $4.04 | +48.51% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $6.63 | +111.16% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $29.78 | -83.21% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.54 | +214.96% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $12.28 | +624.76% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $7.64 | +1,470.68% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $13.38 | +535.28% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.46 | +1,027.17% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $15.94 | +257.59% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.36 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.76 | +118,931.87% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $9.68 | +106.72% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.21 | +48,209.18% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $40.26 | -13.07% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $13.45 | +197.40% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $28.74 | +1,653.65% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $318.91 | -27.88% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $11.70 | +9,515.38% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.91 | +4,295.60% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $28.77 | -25.27% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $48.42 | -51.47% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $182.02
Upside: +1.64%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $7.44
Upside: -19.35%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $7.68
Upside: +121.35%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.21
Upside: +81.00%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $250.16
Upside: -38.04%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $60.83
Upside: -12.87%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $10.99
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $57.37
Upside: +27.24%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $18.87
Upside: +647.22%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $24.04
Upside: +41.43%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $4.04
Upside: +48.51%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $6.63
Upside: +111.16%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $29.78
Upside: -83.21%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.54
Upside: +214.96%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $12.28
Upside: +624.76%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $7.64
Upside: +1,470.68%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $13.38
Upside: +535.28%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.46
Upside: +1,027.17%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $15.94
Upside: +257.59%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.36
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.76
Upside: +118,931.87%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $9.68
Upside: +106.72%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.21
Upside: +48,209.18%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $40.26
Upside: -13.07%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $13.45
Upside: +197.40%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $28.74
Upside: +1,653.65%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $318.91
Upside: -27.88%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $11.70
Upside: +9,515.38%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.91
Upside: +4,295.60%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $28.77
Upside: -25.27%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $48.42
Upside: -51.47%